Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
This page is not indexed by search engines while we improve data quality.
Kenderian Saad — Human Necessities
Kenderian Saad holds 5 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Kenderian Saad |
| Technology | Human Necessities |
| Patents in slice | 5 |
| Recent patents in slice | 0 |
| First year | 2016 |
| Last year | 2019 |
Representative patents
Notable publications linking Kenderian Saad to Human Necessities.
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Recent filings
Latest patents from Kenderian Saad in Human Necessities.
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US-2019336504-A1 · Nov 7, 2019 · US
Related pages
Navigate to parent entity pages.